Ten studies from 2013 with potential to change endocrinology practice were summarized in Annals of Internal Medicine's annual Update in Endocrinology, published in the June 3 issue.
A new consensus report urged clinicians to discuss self-management education and support with all diabetes patients and provide referrals at four critical points in care, including diagnosis.
Mean out-of-pocket spending for all care among a national sample of insured patients with type 1 diabetes was nearly $2,500 in 2018, according to one study, while a second study found that commercially insured patients' out-of-pocket insulin costs
On average during six influenza seasons, the protective effect of the vaccine in preventing influenza hospitalization was 46% for current-season vaccination and 44% for vaccination in prior seasons only, a Spanish study found.
A meta-analysis of six studies found that patient-led titration was associated with lower HbA1c and fasting plasma glucose levels than physician-led titration, although hypoglycemia risk and body weight were slightly higher.
A cohort study found a threefold increase in the risk for diabetic ketoacidosis with sodium-glucose cotransporter-2 (SGLT-2) inhibitors compared to dipeptidyl peptidase-4 (DPP-4) inhibitors, with possible variation by severity or duration of diabetes
The study highlights the role of depression as specific risk factor for death in patients with diabetes after major LEA and suggests including its definition and management in strategies to reduce
In a propensity-matched Scandinavian study, new users of sodium-glucose cotransporter-2 (SGLT-2) inhibitors had a lower risk of renal replacement therapy and hospital admission for renal events than new users of dipeptidyl peptidase-4 (DPP-4)
Unintentional weight loss and weight loss in those with a body mass index already in the normal range were particularly associated with risk of pancreatic cancer among patients with recent-onset diabetes, a study found.
In a systematic review and meta-analysis, no difference was seen between high- and low-dose sodium-glucose cotransporter-2 (SGLT-2) inhibitors in overall safety or specific safety outcomes, other than a mild increased risk for adverse events with